Research article summary (published 3 Oct 2009):

[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]

(Effekt af tesofensine på kropsvaegt og kropssammensaetning hos svaert overvaegtige--sekundaerpublikation.)

Full Abstract

Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised to treatment with Tesofensine 0.25, 0.5, or 1.0 mg, or placebo daily for 24 weeks. Treatment with Tesofensine resulted in a mean weight reduction of 4.5, 9.2 and 10.6% higher than that of placebo for 0.25, 0.5 and 1.0 mg, respectively. Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of safety and efficacy of 0.5 mg Tesofensine need confirmation in phase III trials.

Author information

Author/s: Nielsen, Anne-Louise Hother (AL); Larsen, Thomas Meinert (TM); Madsbad, Sten (S); Breum, Leif (L); Jensen, Thomas Jon (TJ); Kroustrup, Jens Peter (JP); Astrup, Arne (A);

Affiliation: Institut for Human Ernaering, Det Biovidenskabelige Fakultet, Københavns Universitet, DK-1958 Frederiksberg C. alhn(-atsign-)life.ku.dk

Journal and publication information

Publication Type: Clinical Trial, Phase II; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal: Ugeskrift for laeger (Ugeskr Laeger), published in Denmark. (Language: dan)

Reference: 2009-Oct; vol 171 (issue 41) : pp 2974-7

Dates: Created 2009/10/13; Completed 2009/10/20;

PMID: 19824222, status: MEDLINE (last retrieval date: 10/20/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent Adult Aged Anti-Obesity Agents - adverse effects; therapeutic use Bicyclo Compounds, Heterocyclic - adverse effects; therapeutic use Body Composition - drug effects Double-Blind Method Female

Humans Male Middle Aged Obesity - drug therapy Time Factors Treatment Outcome Weight Loss Young Adult

Associated Chemicals: Anti-Obesity Agents (0) ; Bicyclo Compounds, Heterocyclic (0) ; Tesofensine (0)

Related articles

These are the highest related articles currently in the database:

• Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. 20 Oct 2008
• A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. 30 Aug 2000
• Benefits and risks of antiobesity agents. 28 Feb 2000
• Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. 29 Sep 2006
• The good and the bad news: surgery vs. drug therapy. 30 Dec 2007
• Meta-analysis: pharmacologic treatment of obesity. 3 Apr 2005
• A randomized double-blind crossover study of the antiobesity effects of etiocholanedione. 30 Dec 1993
• Is new hope on the horizon for obesity? 27 Nov 2008
• Pharmacologic treatment for obesity. Options for today...and tomorrow. 30 Jul 2006
• Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. 9 Nov 1998

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.